Home administration of lanreotide Autogel by patients with acromegaly, or their partners, is safe and effective

What Was Tested

The paper reports a study of Somatostatin and Lanreotide, published as a clinical trial, phase iv.

The introduction of ready-to-use lanreotide Autogel has presented the possibility of patients receiving their acromegaly treatment at home.

Who Took Part

By PubMed's age tags, the people studied were adults, middle-aged adults, older adults and people over 80, both men and women.

Patients elected either to receive/administer unsupervised home injections after injection technique training (Test group) or continued to receive injections from a healthcare professional (Control group).

Measurements The main outcome measure was the proportion of patients/partners who successfully administered injections throughout the study.

How the Study Was Run

The researchers set it up as an open-label and multicenter study.

Being open-label, the Somatostatin study did not mask who received what.

Running at several centres spread the Somatostatin study over different clinics and patient groups.

The methods mention a period of 40 weeks.

Multicentre (10 UK regional endocrine centres), open-label, nonrandomised, controlled study.

Effects were monitored for up to 40 weeks.

What Was Measured

The subject headings attached to it are Acromegaly, Home Nursing, Peptides, Cyclic, Self Care and Somatostatin.

What This Means in Plain Language

The paper is an open-label and multicenter study of Somatostatin and Lanreotide over 40 weeks.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2008 (Clinical endocrinology), a journal based in England.

More context: the Somatostatin compound page and the Lanreotide compound page.